No Data
BeiGene to Host Investor Webcast Highlighting Key Data From ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
BeiGene Insider Sold Shares Worth $9,190,570, According to a Recent SEC Filing
Beigene issued approximately 0.0504 million shares due to the exercise of stock options.
Beigene (06160) announced that during the period from November 1, 2024, to November 30, 2024, 0.0504 million shares of common stock were issued due to the exercise of stock options by eligible participants (excluding company directors).
Beigene (06160.HK) obtained 0.4931 million shares of restricted stock units due to the restricted share units.
Gelonghui December 2 | Beigene (06160.HK) announced that on November 30, 2024, 0.4931 million shares of common stock will be issued due to the vested restricted stock units granted under the equity plan (excluding the company's directors).
Weilizhizhi is applying to list on the Hong Kong Stock Exchange, positioning itself as a leader in the development of next-generation tumor immunotherapy.
Currently, the heat and activity of the bispecific antibody track are rapidly rising, and it has become a new hot spot in the global innovative drugs industry. Multinational pharmaceutical companies are actively "sweeping the shelves", actively seeking and investing in promising bispecific pipelines. According to the statistics of Bioon, in the first three quarters of 2024, global pharmaceutical companies' transaction activities in the field of bispecific drugs were exceptionally active, with a total of 31 transactions completed. This number exceeds the total annual transaction volume of any year in the past three years, enough to show that the status and influence of bispecific drugs in the global pharmaceutical market are rapidly rising. Among them, there were 5 large BD transactions on bispecific/trispecific drugs in November alone, with high amounts involved.
Insider Sale: Director at $BGNE (BGNE) Sells 200 Shares
No Data
No Data
